This article is for all providers caring for our members
On April 25, the Food and Drug Administration (FDA) approved remdesivir for high-risk, hospitalized children 28 days and older, making it the first COVID-19 treatment available to kids under 12.
Children and infants who weigh at least seven pounds, have tested positive, and are hospitalized or at high risk for severe COVID-19 will be able to access the treatment. The FDA still urges vaccination for those eligible.
Throughout most of the pandemic, children have been far less likely to be hospitalized with COVID-19 than adults. According to the Centers for Disease Control and Prevention, about three out of 100,000 children four and younger were hospitalized with COVID-19 during the Delta surge last September. But during the Omicron surge, which started in December, the risk of a child four and under being hospitalized with COVID-19 grew to five times that number.